Teens with diabetes test smart insulin pumps against surprise breakfasts
NCT ID NCT07455643
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested two automated insulin delivery systems (Medtronic 780G and Tandem t:slim X2) in 20 adolescents with type 1 diabetes. Participants ate breakfasts without telling the device how many carbs they were eating. The goal was to see how well each system controlled blood sugar after these unannounced meals. Results will help improve future closed-loop algorithms to reduce the need for manual insulin dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Automated insulin delivery systems (Medtronic 780G and Tandem t:slim X2 with Control-IQ)
What this could lead to
If successful, this study could help refine closed-loop algorithms to better manage unannounced meals, reducing the burden on teens with type 1 diabetes.
What could go wrong
This is a small pilot study with only 20 participants, so results may not apply to everyone. The findings are preliminary and need confirmation in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" - Catania
Catania, Sicily, 95123, Italy